Cite
HARVARD Citation
Reinhorn, D. et al. (2019). A Cost‐Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First‐Line Intermediate‐ to Poor‐Risk Advanced Renal Cell Carcinoma. Oncologist. pp. 366-371. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Reinhorn, D. et al. (2019). A Cost‐Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First‐Line Intermediate‐ to Poor‐Risk Advanced Renal Cell Carcinoma. Oncologist. pp. 366-371. [Online].